| 查看: 4341 | 回复: 16 | ||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||||
wachina至尊木虫 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失败，恒瑞呋格列泛齿亡唇寒 已有16人参与
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作为慢性疾病：糖尿病的治疗，肝毒性太致命了，难怪武田挥泪斩马谡。值得一提的是，恒瑞也向CFDA申报了GPR-40激动剂呋格列泛，现在心里估计也是拔凉拔凉的 |
回复此楼» 收录本帖的淘帖专辑推荐
 新药仿药 |
» 猜你喜欢
重庆医科大学-人工智能医学学院
已经有1人回复
-
丽水学院材料与能源工程学院招收调剂！（可调剂专业范围广）
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有283人回复
-
晴川万里新书
已经有4人回复
-
在线求助，急！！！请问哪里可以做磁性纳米材料的高分辨透射电镜的测试表征呀？
已经有5人回复
-
福州大学李兴淑教授课题组急招博士研究生
已经有9人回复
-
Liquid Chromatography-Mass Spectrometry Analysis of Small Interfering RNAs
已经有1人回复
-
加巴喷丁胶囊激素6月超限杂质结构
已经有4人回复
-
中药检测种决明子、枳实、水蛭、茯苓品种检测问题交流
已经有0人回复
lu198799
金虫 (正式写手)
- 应助: 7 (幼儿园)
- 金币: 1362.5
- 散金: 2
- 帖子: 454
- 在线: 127.5小时
- 虫号: 775421
- 注册: 2009-05-20
- 性别: GG
- 专业: 合成药物化学
9楼2013-12-31 10:00:56
2楼2013-12-30 12:41:43
3楼2013-12-30 13:06:43
4楼2013-12-30 16:49:55
